Opinion|Videos|December 23, 2024
Navigating REMS Requirements and Educating Other Stakeholders on Bispecific Therapies
Panelists discuss the guidance on managing REMS program compliance for bispecific therapies and strategies for educating non-oncology health care providers about cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) toxicities.
Advertisement
Video content above is prompted by the following
- Each of these bispecific therapies has an associated REMS program. What is involved with these programs, and what best practices can you share on successfully meeting REMS requirements?
- How can institutions educate health care professionals outside of oncology (eg, primary care, emergency department) about CRS and ICANS in the event patients experiencing these toxicities seek care in those settings?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- IVIG Therapy Reduced Infections by 67% in Patients With Multiple Myeloma
September 19th 2025
- IMS 2025: Shifting Immunotherapies to Outpatient Care for Multiple Myeloma
September 19th 2025
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
ACIP Meeting: COVID-19 Vaccines to be Administered Through Shared Clinical Decision-Making
2
ACIP Meeting: Combined MMRV Vaccine, Hepatitis B Vaccine Restricted for Some Age Groups
3
Intelligent Pharmacy: Leveraging AI and Automation to Enhance Patient Care and Pharmacist Roles
4
FDA Approves Keytruda Qlex Subcutaneous Injection for Adult and Pediatric Patients With Solid Tumors
5